Fig. 3: Intrinsic subtype distribution according to HER2 status and HR status.
From: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
HR hormone receptors, TNBC triple-negative breast cancer, IHC immunohistochemistry, ISH in situ hybridization (including either FISH, SISH, and CISH). Number of patients in A (n = 1576), B (n = 1137); C (n = 437); D (n = 673); E (n = 701); F (n = 325).
